Printer Friendly

ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES PRODUCT ACQUISITION AGREEMENT WITH BRISTOL-MYERS SQUIBB

 EATONTOWN, N.J., Aug. 31 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced today that it has signed a letter of intent to acquire a line of currently marketed prescription and nonprescription products from Bristol-Myers Squibb Company. Nine of the ten products to be acquired are directly within Roberts targeted areas of therapeutic focus. The table below lists the territories where Roberts expects to acquire marketing rights for these products.
 Product Tradename Therapeutic Category Geographic
 Market
 Colace(R)/PeriColace(R) Gastroenterology U.S./Canada
 Saluron(R)/Salutensin(R) Cardiovascular U.S./Canada
 Florinef(R) Endocrinology Canada
 Mucomyst Respiratory Canada
 K-Lyte(R) Cardiovascular Canada
 Squibb(R) Mineral Oil Gastroenterology U.S.
 Squibb(R) Glycerin
 Suppositories Gastroenterology U.S.
 Squibb(R) Cod Liver Oil Nutritional U.S.
 The letter of intent provides that Bristol-Myers Squibb will continue to manufacture finished goods for Roberts for a specific period of time. The transaction must be approved by the board of directors of each company and is subject to review by federal agencies. Terms of the agreement were not disclosed; however, the transaction is to be completed on a cash basis and is expected to be completed prior to the end of September.
 Roberts Pharmaceutical Corporation is an international pharmaceutical company focusing on the acquisition and development of late-stage development products and the acquisition of currently marketed prescription and nonprescription products. Roberts currently markets its products in seven countries and has operating subsidiaries in the United States, Canada, and the United Kingdom. Roberts has six prescription pharmaceutical products in late-stage clinical development and currently markets products primarily in six major therapeutic areas: Cardiovascular Respiratory, Gynecology/Endocrinology, Urology, Oncology and Gastroenterology.
 -0- 8/31/93
 /CONTACT: Kristin Payne of Roberts Pharmaceutical, 908-389-1182
 (RPCX)


CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU: LIC

SM-TM -- NY005 -- 7417 08/31/93 10:18 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 31, 1993
Words:306
Previous Article:ROBERTS PHARMACEUTICAL CORPORATION FILES PROPOSED OFFERING OF COMMON STOCK WITH SEC
Next Article:PRINCETON DENTAL MANAGEMENT CORPORATION TO ACQUIRE DENTAL PRACTICES
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters